



LANXESS - Q1 2013 Results Conference Call

A weak start to a challenging year

Axel C. Heitmann, CEO Bernhard Duettmann, CFO




Safe harbor statement


The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.


This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.



Executive overview Q1 2013 Business and financial review Q1 2013 Outlook / Guidance







Agenda

- Executive overview Q1 2013
- Business and financial review Q1 2013
- Outlook / Guidance

LANXESS

Q1 2013 financial overview: Key metrics reflect challenging macro environment

[€ m]	Q1 2012	Q1 2013	yoy in %
Sales	2,388	2,095	-12.3%
EBITDA pre except.	369	174	-52.8%
margin	15.5%	8.3%	
EPS	2.31	0.30	-87%
Capex*	92	93	1.1%
[€ m]	31.12.2012	31.03.2013	Δ%
Net financial debt	1,483	1,787	20.5%
Net working capital	1,849	2,175	11.6%
Employees	17,177	17,381	1.2%
	_		

- Sales decrease due to lower volumes, prices and adverse currency effects
- EBITDA and margin decrease due to lower pricing levels and volumes as well as related idle costs
- EPS decline affected by risen D&A
- Net financial debt increases on the back of weak operating results and increased working capital

Exceptionally weak start of the year

2012 restated due to IAS 19 (revised)
* Net of capitalized borrowing costs, finance lease and projects financed by customers

Q1 2013: P&L impacted by exceptionally weak start of the year

[€ m]	Q1 2	2012	Q1 2	2013	yoy in %
Sales	2,388	(100%)	2,095	(100%)	-12%
Cost of sales	-1,796	(75%)	-1,700	(81%)	-5%
Selling	-186	(8%)	-189	(9%)	2%
G&A	-72	(3%)	-79	(4%)	10%
R&D	-45	(2%)	-48	(2%)	7%
EBIT	277	(12%)	67	(3%)	-76%
Net Income	192	(8%)	25	(1%)	-87%
EPS	2.31		0.30		-87%
EBITDA	365	(15%)	169	(8%)	-54%
thereof exceptionals	-4	(0%)	-5	(0%)	25%
EBITDA pre exceptionals	369	(15.5%)	174	(8.3%)	-53%


- Sales decline as volumes (-6%) and prices (-6%) decrease in a poor market environment, currency slightly negative (-1%)
- COGS increase relatively due to higher D&A, ramp-up costs (~€20 m) and increased headcount
- SG&A increase on storage costs, portfolio effects, salary inflation and projects
- All metrics reflect low demand

Impact from subdued demand clearly visible

2012 restated due to IAS 19 (revised)

LANXESS

Q1 2013: Sales and EBITDA decline across most businesses



Total group sales and EBITDA pre figures include reconciliation
* As of April 1st 2013 BU ION (Ion Exchange Resins) renamed to BU LPT (Liquid Purification Technologies)
**_n^bAs of January 1st 2013 BU TRP (Technical Rubber Products) split into BU KEL (Keltan Elastomers) and BU HPE (High Performance Elastomers)

Performance Polymers: A quarter with poor demand – volume declines and drop in price levels

[€ m]	Q1 2012	Q1 2013	Δ
Sales	1,391	1,134	-18.5%
EBIT	206	52	-74.8%
Depr. / Amort.	48	60	25.0%
EBITDA pre exceptionals	255	112	-56.1%
Margin	18.3%	9.9%	
Capex*	63	58	-7.9%


Q1 comments

- Lower price levels across all BUs; raw-material-driven price declines in BUs PBR and HPE (lower butadiene prices yoy)
 Volume declines in almost all BUs due to continued destocking.
- poor tire demand and European OEM weakness
- BU HPM with positive volumes from high-tech-plastics in Asia and Americas, but burdened by weak Caprolactam business
- Ramp-up costs (~€20 m), technology upgrade for Keltan ACE (~€10 m) and idle costs burden earnings and margin



11

Advanced Intermediates: Solid profitability driven by agro



^{*} Net of capitalized borrowing costs, finance leases and projects financed by customers

LANXESS

LANXESS

12

^{*} Net of capitalized borrowing costs and projects financed by customers

Performance Chemicals: Lower volumes and related idle costs burden EBITDA

[€ m]	Q1 2012	Q1 2013	Δ
Sales	558	520	-6.8%
EBIT	62	29	-53.2%
Depr. / Amort.	21	21	0.0%
EBITDA pre exceptionals	83	51	-38.6%
Margin	14.9%	9.8%	
Capex*	11	19	72.7%

Q1 comments

- Stable prices as price increases in several BUs offset decreases in BU FCC (phosphor chemicals) and BU LEA (chrome ore)
- Volume decline driven by BU IPG (late start of construction in Europe and US), BU LEA (CO₂ instability) and BU MPP
- Lower volumes in BUs RCH and RUC (weak tire markets)
- EBITDA burdened by lower utilization rates; related idle costs
- Capex increases due to CO₂ facility in South Africa (BU LEA) and growth projects in China (BUs LEA and IPG)



12

LANXESS

Q1 2013 results burden balance sheet KPIs

[€ m]	Dec 2012	Mar 2013	Δ
Total assets/liabilities	7,519	7,603	1%
Equity	2,330	2,386	2%
Equity ratio	31%	31%	
Net financial debt	1,483	1,787	20%
Net financial debt/EBITDA	1.21	1.73	
Near cash, cash & cash equivalents	797	529	-34%
Pension provisions	893	915	2%
ROCE	15.6%	11.5%	
Net Working capital	1,849	2,175	18%
Net Working capital / sales	20%	25%	
DSI (in days)*	65	71	9%
DSO (in days)*	47	53	13%

- Net financial debt increases due to higher working capital and weak operational results
- Net financial debt/EBITDA increases with both lower EBITDA and higher net debt
- Higher inventories due to weak demand level in Q1 2013
- Increased DSO: Receivables increase as sales in March 2013 are up vs December 2012

LANXESS

14

^{*} Net of capitalized borrowing costs and projects financed by customers

^{*}Days of Sales Inventory / Days of Sales outstanding calculated on quarterly sales 2012 restated due to IAS 19 (revised)

Q1 2013: Poor results weigh on operating cash flow

[€ m]	Q1 2012	Q1 2013
Profit before tax	247	31
Depreciation & amortization	88	102
Gain from sale of assets	0	0
Result from equity investments	-3	0
Financial (gains) losses	24	25
Cash tax payments / refunds	-3	-34
Changes in other assets and liabilities	20	1
Operating cash flow before changes in WC & CTA	373	125
Changes in working capital	-244	-285
CTA funding*	0	0
Operating cash flow	129	-160
Investing cash flow	9	144
thereof capex**	-92	-93
Financing cash flow	17	-19

- Lower business performance leads to reduced profit before
- D&A increases as new assets come on stream
- Higher receivables and inventory levels (volume driven) increase working capital
- Operating cash flow burdened from low earnings and higher working capital
- Investing cash flow includes release of near cash assets

2012 restated due to IAS 19 (revised)

LANXESS

Agenda

- Executive overview Q1 2013
- Business and financial review Q1 2013
- **Outlook / Guidance**



^{*} CTA (Contractual Trust Arrangement) funding formerly shown in investing cash flow "Net of capitalized borrowing cost , finance lease and projects financed by customers

A tough start of the year – muted expectations for FY 2013

Current macro view - ongoing uncertainty due to low visibility

- Overall customer demand remains at low levels, only slightly improving in Q2
- No substantial improvement of economic environment and low visibility persisting
- Customer destocking expected to slow down in Q2; inventories remain tightly managed
- Slight growth in the U.S., Europe remains weak, Asia expected to pick up in H2

LANXESS expects a challenging year 2013

- Demand fluctuations managed in-house: flexible asset and cost management implemented
- "Price-before-volume" strategy continues despite ongoing poor demand and market price pressure: Q2 EBITDA pre improving sequentially, but not better than ~€220 m
- We see EBITDA pre below €1 bn in 2013
- We expect a pick-up in demand in H2 2013




LANXESS

17

LANXESS

Energizing Chemistry



Housekeeping items for consideration

Additional financial expectations

• Capex 2013:

reduced to ~€600 m

D&A 2013:

~€420 - €440 m

Reconciliation 2013:

~€200 m mainly as R&D activities increase

Exceptional items Q2 2013:

mid double-digit € million amount

Annual tax rate:

- mid-term: ~22%

- short-term: depending on regional profit contribution and respective tax regimes – tax rate may increase

• Hedging 2013: Hedging 2014: ~50% at 1.25 -1.35 USD / EUR ~30% at 1.25 -1.35 USD / EUR

IAS 19 revised; impact in 2013:

- operational result: low single-digit € million amount

- financial result: low single-digit € million





Balance sheet proves strong backbone

[€ m]	Mar'12	Dec '12	Mar'13		Mar'12	Dec '12	Mar'13
Non-current assets	3,496	3,747	3,849	Stockholders' equity	2,225	2,330	2,386
Intangible assets	365	390	399	Non-current liabilities	2,824	3,559	3,629
Property, plant & equipment	2,676	2,994	3,084	Pension & post empl. provis.	750	893	915
Equity investments	15	. 8	0	Other provisions	313	304	304
Other investments	31	18	22	Other financial liabilities	1,535	2,167	2,200
Other financial assets	71	8	7	Tax liabilities	60	35	35
Deferred taxes	212	211	219	Other liabilities	88	78	97
Other non-current assets	126	118	118	Deferred taxes	78	82	78
Current assets	3,645	3,772	3,754	Current liabilities	2,092	1,630	1,588
Inventories	1,446	1,527	1,641	Other provisions	491	440	478
Trade accounts receivable	1,301	1,117	1,244	Other financial liabilities	604	167	191
Other financial & current assets	338	331	340	Trade accounts payable	755	795	710
Near cash assets	227	411	176	Tax liabilities	64	45	31
Cash and cash equivalents	333	386	353	Other liabilities	178	183	178
Total assets	7,141	7,519	7,603	Total equity & liabilities	7,141	7,519	7,603

- Inventories increase due to weak demand in Q1 2013
- Trade accounts receivables increase sequentially as March 2013 sales higher compared to sales in December 2012
- Other financial liabilities reduced mainly due to the scheduled repayment of the €400 m bond in June 2012


LANXESS

21

A well managed and conservative maturity profile

Long term financing secured

- Well balanced maturity profile
- Diversified financing sources
 - Bonds
 - Private placements
 - Syndicated credit facility
 - Development banks
 - Bilateral bank facilities
- €1.25 bn RCF and €200 m credit facility with EIB^{*} undrawn




* European Investment Bank; final maturity of EIB financing in case of utilization in 2017 or later; EIB facility currently undrawn

LANXESS

22





Overview exceptional items Q1 2012 and Q1 2013

[€ m]	Q1 :	2012	Q1 2	2013
	Exceptional	thereof D&A	Exceptional	thereof D&A
Performance Polymers	1	0	0	0
Advanced Intermediates	0	0	0	0
Performance Chemicals	0	0	1	0
Reconciliation	3	0	4	0
Total	4	0	5	0

LANXESS

Abbreviations

	Performance Polymers		Performance Chemicals
BTR PBR KEL* HPE*	Butyl Rubber Performance Butadiene Rubbers Keltan Elastomers High Performance Elastomers High Performance Materials	MPPIPGFCCLEARCHRUCLPT**	Material Protection Products Inorganic Pigments Functional Chemicals Leather Rhein Chemie Rubber Chemicals Liquid Purification Technologies
	Advanced Intermediates		
• All • SGO	Advanced Industrial Intermediates Saltigo		

* As of January 1st 2013 BU TRP split into BU KEL (Keltan Elastomers) and BU HPE (High Performance Elastomers)
** As of April 1st 2013 BU ION (Ion Exchange Resins) renamed to BU LPT

Upcoming events

2013

November 14

May 14/15 Deutsche Bank German Swiss & Austrian Conference Deutsche Bank 4th Annual Asia Conference 2013 May 20/21 AGM 2013 May 23 Oddo Securities Canada Conference May 28/29 Morgan Stanley Sustainable and Responsible Investment Day June 6 Goldman Sachs European Chemicals 2020 June 18/19 MainFirst Chemical One-on-One Forum June 27 Q2 results 2013 August 6 Jefferies 2013 Gobal Industrial Conference August 14 Commerzbank Chemicals & Life Science Conference August 27 September 19 Analyst Roundtable 2013 Berenberg / Goldman Sachs German Corporate Conference 2013 September 23/24 Baader Investment Conference September 25 Berenberg Chemicals Conference October 1 Q3 results 2013 November 12

LANXESS

Frankfurt

Singapore

Montreal/Toronto

Cologne

London

London

Frankfurt

New York

Frankfurt

Cologne

Munich

Munich

London

Boston

Contact details Investor Relations

Oliver

Head of Investor Relations



Morgan Stanley Global Chemicals Conference

: +49-214 30 49611 : +49-214 30 959 49611 : +49-175 30 49611 : Oliver.Stratmann@lanxess.com Fax. Mobile Email



Tel. : +49-214 30 23851 Fax. : +49-214 30 40944 Mobile : +49-175 30 23851 Email : Verena.Kehrenberg@lanxess.com





Fax. : +49-214 30 40944 Mobile : +49-175 30 58007 Email : Dirk.Winkels@lanx

LANXESS IR website

Tanja Satzer Private Investors / AGM



Tel. : +49-214 30 43801 Fax. : +49-214 30 959 43801 Mobile : +49-175 30 43801 Email : Tanja.Satzer@lanxess.com

Institutional Investors Analysts



Tel. : +49-214 30 50458 Fax. : +49-214 30 40944 Mobile : +49-175 30 50458 Email : Ulrike.Weihs@lanxess.com

Institutional Investors



: +49-214 30 42030 Fax. : +49-214 30 40944 Mobile : +49-175 30 42030 Email : Joachim.Kunz@lanxess.com

